A 52-year-old woman presents with bilateral hand pain and morning stiffness lasting 90 minutes. Her metacarpophalangeal joints are swollen and tender. This clinical picture immediately raises suspicion for inflammatory arthritis, specifically , where early recognition transforms outcomes. Meanwhile, in the haematology clinic, a 68-year-old man's routine bloods reveal haemoglobin of 92 g/L with microcytosis-triggering a systematic approach to . These scenarios exemplify the precision required in rheumatological and haematological diagnosis.
Essential Classifications:
Inflammatory arthropathies:
Anaemia classification by MCV:
Venous thromboembolism (VTE) risk stratification:
📌 Mnemonic for RA criteria (ACR/EULAR 2010): JSDAS - Joint involvement, Serology (RF/anti-CCP), Duration (≥6 weeks), Acute phase reactants, Score ≥6/10 confirms diagnosis
| Condition | Key Diagnostic Feature | Prevalence/Incidence |
|---|---|---|
| Rheumatoid arthritis | Anti-CCP antibody (98% specificity) | 1% UK population |
| Gout | Serum urate >360 μmol/L + crystals | 2.5% prevalence, M:F 3:1 |
| Iron deficiency anaemia | Ferritin <30 μg/L | Most common anaemia worldwide |
| Pulmonary embolism | Wells score + D-dimer/CTPA | 60-70 per 100,000/year |


Rheumatoid arthritis exemplifies autoimmune-driven inflammation. Genetic susceptibility (HLA-DR4) combines with environmental triggers (smoking, infection) to breach immune tolerance. Anti-citrullinated protein antibodies (anti-CCP) target synovial proteins, initiating complement activation and cytokine release-particularly TNF-α, IL-6, and IL-1. This inflammatory cascade drives synovial hyperplasia, pannus formation, and cartilage destruction. Understanding this pathway explains why early DMARD therapy in prevents irreversible joint damage within the critical 3-month window.
Mechanistic Insights:
Crystal arthropathy pathogenesis :
Anaemia mechanisms require systematic investigation :
VTE pathophysiology (Virchow's triad):
| Mechanism | Clinical Manifestation | Therapeutic Target |
|---|---|---|
| TNF-α overproduction | Synovial inflammation, erosions | Anti-TNF biologics (adalimumab) |
| IL-1β in gout | Acute inflammatory flare | IL-1 inhibitors (canakinumab) |
| Hepcidin elevation | Anaemia of chronic disease | Treat underlying inflammation |
| Factor Xa activation | Thrombus propagation | DOACs (apixaban, rivaroxaban) |
A 45-year-old presents with sudden-onset first metatarsophalangeal joint pain, erythema, and inability to weight-bear. Serum urate is 520 μmol/L, and joint aspiration reveals negatively birefringent needle-shaped crystals-confirming gout . Meanwhile, a 72-year-old with breathlessness has Wells score 6.5 (PE likely); D-dimer is 850 ng/mL, and CTPA confirms segmental pulmonary embolus . These cases demonstrate guideline-concordant diagnostic pathways.
Evidence-Based Investigation Sequences:
RA diagnostic workup (NICE NG100):
Anaemia investigation pathway :
VTE diagnosis (NICE NG158):


Acute monoarthritis demands rapid differentiation between gout, pseudogout, septic arthritis, and trauma. Septic arthritis is the critical emergency-joint aspiration must occur before antibiotics if feasible. Synovial fluid WCC >50,000/mm³ with neutrophil predominance suggests sepsis, while crystals confirm crystal arthropathy . In anaemia, distinguishing iron deficiency from thalassaemia trait prevents unnecessary iron supplementation: ferritin differentiates, but both cause microcytosis .
Key Discriminators:
Monoarthritis differential:
Microcytic anaemia differentiation:
| Feature | Gout | Pseudogout | Septic Arthritis |
|---|---|---|---|
| Onset | Hours | Hours-days | Hours |
| Joint | 1st MTP (70%) | Knee (50%) | Any (knee commonest) |
| Crystals | Negative birefringent | Weak positive | None |
| Synovial WCC | 2,000-50,000 | 2,000-50,000 | >50,000 |
| Temperature | Usually afebrile | Usually afebrile | Fever >38°C |
Early aggressive DMARD therapy in follows NICE NG100: methotrexate 15-25 mg weekly with folic acid 5 mg weekly (not on methotrexate day) is first-line. Treatment target is remission (DAS28 <2.6) or low disease activity. Failure after 3 months at therapeutic dose warrants escalation to dual/triple DMARD or biologic therapy (anti-TNF, rituximab, tocilizumab). For VTE , NICE NG158 recommends DOACs (apixaban 10 mg BD for 7 days, then 5 mg BD) over warfarin for most patients.
Specific Treatment Protocols:
Acute gout management (NICE CG177):
Anaemia treatment depends on cause:
VTE anticoagulation duration:
| Drug | Dose | Monitoring | Key Adverse Effect |
|---|---|---|---|
| Methotrexate | 15-25 mg weekly | FBC, LFTs fortnightly × 6, then monthly | Hepatotoxicity, pneumonitis |
| Allopurinol | 100-900 mg OD | U&Es, LFTs baseline | Hypersensitivity (stop immediately) |
| Apixaban (PE) | 10 mg BD × 7d, then 5 mg BD | Renal function annually | Bleeding (no routine monitoring) |
| Ferrous sulphate | 200 mg TDS | Hb at 2-4 weeks | GI upset, constipation |
A 78-year-old with RA, CKD stage 3b, and recent PE presents a management challenge. Methotrexate dose requires reduction (10 mg weekly if eGFR 30-50); apixaban needs dose adjustment (2.5 mg BD if ≥2 of: age ≥80, weight ≤60 kg, creatinine ≥133 μmol/L). Concurrent anaemia investigation reveals microcytosis; ferritin is 180 μg/L-suggesting anaemia of chronic disease from RA rather than iron deficiency. This case exemplifies real-world complexity requiring synthesis across rheumatology, haematology, and renal medicine.
Special Population Considerations:
Pregnancy and VTE :
Elderly with crystal arthropathy :
Complications requiring vigilance:
| Comorbidity | Drug Adjustment | Monitoring Frequency |
|---|---|---|
| CKD stage 3b (eGFR 30-44) | Methotrexate 10 mg weekly | FBC, LFTs, U&Es fortnightly |
| Age ≥80 + weight ≤60 kg | Apixaban 2.5 mg BD | Annual renal function |
| Heart failure | Avoid NSAIDs | Consider colchicine for gout |
Key Take-Aways:
Essential Rheumatology & Haematology Numbers:
| Parameter | Threshold | Clinical Significance |
|---|---|---|
| Anti-CCP | >5 U/mL | 98% specificity for RA |
| Serum urate | >360 μmol/L | Hyperuricaemia, gout risk |
| Ferritin | <30 μg/L | Iron deficiency |
| MCV | <80 fL / >100 fL | Microcytic / macrocytic anaemia |
| D-dimer age-adjusted | Age × 10 μg/L (if >50 years) | Improves specificity in elderly |
| Wells score PE | >1 | PE likely, proceed to CTPA |
Key Principles/Pearls:
Quick Reference:
| Condition | First-Line Treatment | Key Monitoring |
|---|---|---|
| Rheumatoid arthritis | Methotrexate 15-25 mg weekly + folic acid 5 mg weekly | FBC, LFTs monthly after stabilization |
| Acute gout | Naproxen 750 mg stat, then 250 mg TDS | Avoid allopurinol during flare |
| Iron deficiency anaemia | Ferrous sulphate 200 mg TDS | Hb at 2-4 weeks, continue 3 months post-normal |
| Pulmonary embolism | Apixaban 10 mg BD × 7d, then 5 mg BD | Annual renal function |
Have doubts about this lesson?
Ask Rezzy, our AI tutor, to explain anything you didn't understand
Test your understanding with these related questions
A 38-year-old woman presents with recurrent episodes of severe abdominal pain and psychiatric symptoms. Her urine turns dark during attacks. Family history reveals similar episodes. What is the inheritance pattern?